The Iliac/SFA/Popliteal Center

Filter Your Results

 

News

 

Initial Data Presented on Eurocor’s Freeway Drug-Eluting Balloon

February 2, 2012—Eurocor GmbH (Bonn, Germany) announced that data from its ongoing FREEWAY study were presented at a company-sponsored symposium during the 2012 Leipzig Inte…

Editor’s Challenge

January 2012—A panel of interventional experts weighs in on how they would access and treat a series of challenging access case presentations.
With John H. Rundback, MD, FSVM, FAHA, FSIR; Mark W. Burket, MD; Bruce H. Gray, DO; Craig Walker, MD; and Michael Wholey, MD, MBA

DURABILITY II 1-Year Data Presented for Covidien’s EverFlex Stent to Treat SFA Disease

January 24, 2012—Covidien (Mansfield, MA) announced that Co-National Principal Investigator Jon Matsumura, MD, presented 1-year results from the DURABILITY II study of the c…

ESPRIT I in Europe Evaluates Abbott’s Drug-Eluting BVS for PAD

December 22, 2011—Abbott Vascular (Santa Clara, CA) announced the initiation of the ESPRIT I clinical trial in Europe.The company stated that ESPRIT I is a single-arm, multi…

Bard Acquires Lutonix

December 20, 2011—CR Bard, Inc. (Murray Hill, NJ) announced that it has acquired Lutonix, Inc. (Maple Grove, MN) for approximately $225 million to be paid at closing, with a…

Two-Year Data Published for Idev’s Supera Stent in Treatment of SFA Disease

December 15, 2011—Idev Technologies, Inc. (Webster, TX) announced that 24-month data on the company’s Supera wire interwoven nitinol stent were published by Dierk Scheiner…

COBRA Supports SFA Treatment With Boston Scientific’s PolarCath in Diabetic Patients

November 11, 2011—Boston Scientific Corporation (Natick, MA) announced that Principal Investigator Subhash Banerjee, MD, presented data from the COBRA clinical trial during …

SFA: A Closer Look

John R. Laird, MD

October 2011—Most if not all of today’s vascular practices spend considerable portions of their clinical schedules addressing occlusive disease in the superficial femoral artery (SFA)…

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.